Longeveron (LGVN) Price & Analysis

Compare

587 Followers

LGVN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.63 - $2.48

Previous CloseN/A

Volume215.49K

Average Volume (3M)1.49M

Market Cap

$15.75M

Enterprise Value$10.32M

Total Cash (Recent Filing)$10.33M

Total Debt (Recent Filing)$639.00K

Price to Earnings (P/E)―

Beta1.42

Next Earnings

Nov 07, 2025

EPS Estimate

-0.26

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.33

Shares Outstanding19,312,218

10 Day Avg. Volume438,482

30 Day Avg. Volume1,492,618

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.66

Enterprise Value/Revenue4.98

Enterprise Value/Gross Profit6.32

Enterprise Value/Ebitda-0.55

Forecast

1Y Price Target

$3.50

Price Target Upside366.67% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

PartnershipsThe company is exploring partnerships for laromestrocel in Alzheimer's disease, following positive results from a Type B meeting that supported a pivotal study.

Regulatory SupportThe FDA's ongoing commitment to streamlining approvals for rare diseases, particularly rare pediatric diseases, is expected to support the company's filing on a positive note.

Research And DevelopmentLongeveron is making progress in its study of laromestrocel in HLHS, with topline data expected in 2026, which could support registration and potential approval by 2027.

Bears Say

Equity FinancingThe company's recent equity financing has led to dilution, which has contributed to a lowered 12-month price target from $6.00 to $4.00.

Stock Price TargetThe recent equity financing has led to a reduced 12-month price target from $6.00 to $4.00, presenting a less favorable outlook for the stock.

Longeveron News

Longeveron CEO Wa’el Hashad to step down

Longeveron (LGVN) announced leadership updates. The company’s board of directors has appointed Than Powell as interim CEO, effective...

15d ago

LGVN

Longeveron Announces Leadership Changes Amidst CEO Departure

Longeveron ( ($LGVN) ) has issued an announcement. On August 27, 2025, Longeveron Inc. announced a leadership change...

15d ago

LGVN

Longeveron Inc. Earnings Call: Progress Amid Challenges

Longeveron Inc. (($LGVN)) has held its Q2 earnings call. Read on for the main highlights of the call....

18d ago

LGVN

Longeveron: Buy Rating Backed by Promising Clinical Developments and Strategic Financial Outlook

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on LGVN stock, giving a Buy rating yesterday....

1M ago

LGVN

Longeveron price target lowered to $3 from $10 at Roth Capital

Roth Capital lowered the firm’s price target on Longeveron (LGVN) to $3 from $10 and keeps a Buy...

1M ago

LGVN

Longeveron Inc. Faces Regulatory and Manufacturing Challenges Threatening Financial Stability

Longeveron Inc. (LGVN) has disclosed a new risk, in the Manufacturing category. Longeveron Inc. faces significant business risks...

1M ago

LGVN

Longeveron Inc. Reports Q2 2025 Financial Results

Longeveron Inc. ( ($LGVN) ) has released its Q2 earnings. Here is a breakdown of the information Longeveron...

1M ago

LGVN

Longeveron Closes $5 Million Public Stock Offering

Longeveron ( ($LGVN) ) has issued an announcement. On August 8, 2025, Longeveron announced the pricing of a...

1M ago

LGVN

LGVN Earnings this Week: How Will it Perform?

Longeveron Inc. (LGVN) is scheduled to report 2nd quarter earnings on 08/13/2025, after the market closes. Regarding Q2...

1M ago

LGVN

Longeveron announces $17.5M Class A common stock offering

Longeveron (LGVN) announced the pricing of a public offering of 5.88M of the company’s Class A common stock,...

1M ago

LGVN

Longeveron files to sell 3.85M shares of Class A common stock

16:05 EDT Longeveron (LGVN) files to sell 3.85M shares of Class A common stock Published first on TheFly...

2M ago

LGVN

Longeveron licenses patent for stem cell technology from University of Miami

Longeveron (LGVN) has licensed an issued US patent for a stem cell technology from the University of Miami....

2M ago

LGVN

Longeveron Gains FDA Approval for Laromestrocel Trial

An announcement from Longeveron ( ($LGVN) ) is now available. On July 8, 2025, Longeveron Inc. announced that...

2M ago

LGVN

Longeveron Receives Buy Rating: Promising Pipeline and Strategic Expansion into Pediatric Cardiomyopathy

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Longeveron, with a...

2M ago

LGVN

LGVN FAQ

What was Longeveron’s price range in the past 12 months?

Longeveron lowest stock price was $0.63 and its highest was $2.48 in the past 12 months.

What is Longeveron’s market cap?

Longeveron’s market cap is $15.75M.

When is Longeveron’s upcoming earnings report date?

Longeveron’s upcoming earnings report date is Nov 07, 2025 which is in 49 days.

How were Longeveron’s earnings last quarter?

Longeveron released its earnings results on Aug 13, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.35 by $0.02.

Is Longeveron overvalued?

According to Wall Street analysts Longeveron’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Longeveron pay dividends?

Longeveron does not currently pay dividends.

What is Longeveron’s EPS estimate?

Longeveron’s EPS estimate is -0.26.

How many shares outstanding does Longeveron have?

Longeveron has 19,312,218 shares outstanding.

What happened to Longeveron’s price movement after its last earnings report?

Longeveron reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.35. Following the earnings report the stock price went down -11.628%.

Which hedge fund is a major shareholder of Longeveron?

Currently, no hedge funds are holding shares in LGVN

Company Description

Longeveron

Longeveron Inc. is a biotechnology company focused on developing cellular therapies for aging-related and life-threatening conditions. The company is engaged in the research and development of regenerative medicine, specializing in the use of medicinal signaling cells (MSCs) derived from donor bone marrow. Longeveron aims to harness the potential of these cells to address medical conditions associated with aging, such as frailty, and other severe diseases, thereby improving patient outcomes and enhancing quality of life.

Longeveron (LGVN) Earnings & Revenues

Historic Earnings Reports

LGVN Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call highlighted significant progress in clinical trials and pipeline expansion, alongside strategic moves in manufacturing readiness and financial planning. However, these were tempered by declines in revenue and increased expenses, alongside some regulatory and financial uncertainties.View all LGVN earnings summaries

LGVN Stock 12 Month Forecast

Average Price Target

$3.50

▲(366.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.82,1.0646153846153845,1.3092307692307692,1.5538461538461537,1.7984615384615386,2.043076923076923,2.2876923076923075,2.5323076923076924,2.776923076923077,3.0215384615384613,3.266153846153846,3.5107692307692306,3.755384615384615,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.82,1.0261538461538462,1.2323076923076923,1.4384615384615385,1.6446153846153846,1.850769230769231,2.056923076923077,2.263076923076923,2.4692307692307693,2.6753846153846155,2.8815384615384616,3.0876923076923077,3.293846153846154,{"y":3.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.82,0.9876923076923076,1.1553846153846155,1.323076923076923,1.4907692307692306,1.6584615384615384,1.8261538461538462,1.9938461538461536,2.1615384615384614,2.329230769230769,2.496923076923077,2.6646153846153844,2.832307692307692,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.74,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.04,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.03,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >